Correlation Engine 2.0
Clear Search sequence regions

  • angiogenesis (1)
  • antigen (2)
  • BRG1 (1)
  • cohorts (1)
  • factor (4)
  • female (1)
  • gene (1)
  • humans (1)
  • Ifngr2 (1)
  • mice (2)
  • mice balb c (1)
  • mice knockout (1)
  • patient (1)
  • PBRM1 (9)
  • receptor 2 (1)
  • renal cell carcinoma (5)
  • STAT1 (5)
  • target genes (1)
  • Sizes of these terms reflect their relevance to your search.

    A non-immunogenic tumor microenvironment (TME) is a significant barrier to immune checkpoint blockade (ICB) response. The impact of Polybromo-1 (PBRM1) on TME and response to ICB in renal cell carcinoma (RCC) remains to be resolved. Here we show that PBRM1/Pbrm1 deficiency reduces the binding of brahma-related gene 1 (BRG1) to the IFNγ receptor 2 (Ifngr2) promoter, decreasing STAT1 phosphorylation and the subsequent expression of IFNγ target genes. An analysis of 3 independent patient cohorts and of murine pre-clinical models reveals that PBRM1 loss is associated with a less immunogenic TME and upregulated angiogenesis. Pbrm1 deficient Renca subcutaneous tumors in mice are more resistance to ICB, and a retrospective analysis of the IMmotion150 RCC study also suggests that PBRM1 mutation reduces benefit from ICB. Our study sheds light on the influence of PBRM1 mutations on IFNγ-STAT1 signaling and TME, and can inform additional preclinical and clinical studies in RCC.


    Xian-De Liu, Wen Kong, Christine B Peterson, Daniel J McGrail, Anh Hoang, Xuesong Zhang, Truong Lam, Patrick G Pilie, Haifeng Zhu, Kathryn E Beckermann, Scott M Haake, Sevinj Isgandrova, Margarita Martinez-Moczygemba, Nidhi Sahni, Nizar M Tannir, Shiaw-Yih Lin, W Kimryn Rathmell, Eric Jonasch. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nature communications. 2020 May 01;11(1):2135

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 32358509

    View Full Text